Table 2.

Univariate and multivariate analysis of the baseline characteristics to predict the development of erosions in EPP.

Covariates	Univariate Model			Multivariate Model
				Full Model			Reduced Model
	OR	95% CI	p	OR	95% CI	p	OR	95% CI	p
Age, 1-yr increase	1.02	0.99–1.05	0.19	1.02	0.98–1.07	0.31
Sex, males vs females	1.01	0.50–2.06	0.97	1.09	0.49–2.44	0.84
Duration of psoriasis, 1-yr increase	0.98	0.96–1.01	0.24	0.94	0.90–0.98	0.005	0.96	0.93–0.99	0.03
Duration of PsA, 1-yr increase	1.06	0.99–1.13	0.09	1.05	0.98–1.12	0.22
Race, white vs other	1.78	0.63–5.07	0.28	2.02	0.64–6.43	0.23
Active joint count, 1-unit increase	1.12	1.05–1.20	0.001	1.09	1.01–1.17	0.03	1.09	1.02–1.17	0.01
Damaged joint count, 1-unit increase	2.35	1.12–4.96	0.02	2.29	1.06–4.97	0.03	2.43	1.14–5.17	0.02
Medications^*	1.65	1.09–2.48	0.02	1.18	0.74–1.89	0.48

↵* Medications are defined as 0 = none, 1 = NSAID, 2 = DMARD ± NSAID, 3 = biologics ± DMARD ± NSAID. EPP: erosion-present patients; PsA: psoriatic arthritis; NSAID: nonsteroidal antiinflammatory drugs; DMARD: disease-modifying antirheumatic drugs.